Value, affordability and decision making

News
March 2018

Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Economics of Innovation

2017 OHE Annual Report to the Charity Commission

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

News
November 2017

OHE at ISPOR’s 20th Annual European Congress in Glasgow

News
October 2017

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017

00
11
12
13
14
15
16
17
18
19
00

Latest Research & Publications

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

The UK Biotech Sector and Brexit: Past Performance and Future Prospects

New Methods for Analysing the Distribution of EQ-5D Observations

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

All Publications

Filter results by

Filter results by

Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

2017 OHE Annual Report to the Charity Commission

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Real World Evidence for Coverage Decisions: Opportunities and Challenges

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

OHE at ISPOR’s 20th Annual European Congress in Glasgow

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? A Summary of a Symposium held at HTAi Rome 2017

Share on Mastodon